Chinese Drugmaker Agrees to Buy Out Singapore Biotech SciGen
Chinese drug maker Yifan Pharmaceutical Co. agreed to acquire a controlling stake in the Singapore biopharmaceutical company SciGen Ltd. in a deal worth as much as $28 million, the Zhenjiang-based company said in an exchange filing Wednesday.
Yifan offered $0.05 a share to acquire at least 90% of Australian Stock Exchange-listed SciGen in an effort to take the company private. A full takeover would value SciGen at $28 million, according to Yifan.
- 1China Mulls Ban on Transporting Coal, Ore, Steel by Truck
- 2Update: China Abruptly Ends Anti-Dumping Probe Against U.S. Sorghum
- 3Quick Take: Nigeria Awards $6.7 Billion Rail Project To China
- 4Carrefour Opens New Tech-Infused Grocery Store in Shanghai
- 5U.S., China Strike Trade Deal, Ending Threat of Protective Tariffs
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas